Effectiveness of Influenza Vaccine in Patients on Hemodialysis--a Review

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2013 Nov 19

PMID 24241247

Citations 20

Authors

Agnieszka Mastalerz-Migas

Elzbieta Gwiazda

Lidia B Brydak

Affiliations

Soon will be listed here.

Abstract

The influenza virus is one of the most common causes of viral respiratory tract infections. Some chronic diseases predispose to a severe course of the disease and increase the risk of complications and death. To minimize the risk of infection and complications, care of patients with increased risk should include prophylactic measures such as the administration of a seasonal influenza vaccine. An influenza vaccine is the best and cheapest method of influenza prevention. It is indicated for patients with chronic kidney disease, both during conservative treatment and renal replacement therapy. Many studies that have assessed the efficacy of an influenza vaccine in patients on hemodialysis have found that immune deficiency predisposes these patients to infection and a severe course of the disease. Because the immune response to a standard influenza vaccine in this population is weak, the studies covered many aspects of vaccination, including the need for a booster dose. Unlike in a healthy population, the efficacy of an influenza vaccine in patients on hemodialysis might be insufficient; however, the vaccine is still able to induce immunity in a significant number of patients. Considering the latest data and the results of studies described above, the recommendation of a seasonal influenza vaccine should be obligatory in all hemodialysis patients. This paper is based on original articles available from Medline database. The most recent and most significant literature on the influenza vaccine in patients on hemodialysis has been reviewed.

Citing Articles

Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms.

Wall N, Lamerton R, Ashford F, Perez-Toledo M, Jasiulewicz A, Banham G Vaccines (Basel). 2025; 13(1).

PMID: 39852786 PMC: 11768972. DOI: 10.3390/vaccines13010007.

Dialysis Patients Respond Adequately to Influenza Vaccination Irrespective of Dialysis Modality and Chronic Inflammation.

Pleros C, Adamidis K, Kantartzi K, Griveas I, Baltsavia I, Moustakas A J Clin Med. 2023; 12(19).

PMID: 37834849 PMC: 10573409. DOI: 10.3390/jcm12196205.

The Entangled World of Memory T Cells and Implications in Transplantation.

Alexander K, Ford M Transplantation. 2023; 108(1):137-147.

PMID: 37271872 PMC: 10696133. DOI: 10.1097/TP.0000000000004647.

Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis.

Ma B, Tam A, Chan K, Ma M, Hung I, Yap D Front Med (Lausanne). 2022; 9:827859.

PMID: 35355604 PMC: 8959490. DOI: 10.3389/fmed.2022.827859.

Decreased response to the mRNA anti-SARS-CoV-2 vaccine in hepatitis B vaccine non-responders and frail patients treated with peritoneal dialysis.

Kolland M, Riedl R, Bachler B, Ribitsch W, Niedrist T, Meissl A Nephrol Dial Transplant. 2022; 37(6):1188-1190.

PMID: 35137203 PMC: 9383466. DOI: 10.1093/ndt/gfac031.

References

Yoon J, Pahl M, Vaziri N . Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int. 2006; 71(2):167-72. DOI: 10.1038/sj.ki.5002019. View

Kaszubowska L . Telomere shortening and ageing of the immune system. J Physiol Pharmacol. 2009; 59 Suppl 9:169-86. View

Ott U, Sauerbrei A, Lange J, Schafler A, Walther M, Wolf G . Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol. 2012; 201(3):297-302. DOI: 10.1007/s00430-012-0231-8. View

Agrawal S, Gollapudi P, Elahimehr R, Pahl M, Vaziri N . Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant. 2009; 25(3):737-46. DOI: 10.1093/ndt/gfp580. View

Girndt M, Sester M, Sester U, Kaul H, Kohler H . Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl. 2001; 78:S206-11. DOI: 10.1046/j.1523-1755.2001.59780206.x. View

Chang Y, Guo C, Tsai M, Cheng Y, Lin M, Chen C . Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Vaccine. 2012; 30(33):5009-18. DOI: 10.1016/j.vaccine.2012.05.016. View

de Jong J, Beyer W, Palache A, Rimmelzwaan G, Osterhaus A . Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000; 61(1):94-9. View

. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2012; 61(32):613-8. View

Kunisaki K, Janoff E . Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8):493-504. PMC: 2775097. DOI: 10.1016/S1473-3099(09)70175-6. View

10.

Lisowska K, Debska-Slizien A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski J . Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol. 2011; 32(1):189-200. PMC: 3276768. DOI: 10.1007/s10875-011-9603-x. View

11.

Vaziri N, Pahl M, Crum A, Norris K . Effect of uremia on structure and function of immune system. J Ren Nutr. 2011; 22(1):149-56. PMC: 3246616. DOI: 10.1053/j.jrn.2011.10.020. View

12.

Mastalerz-Migas A, Steciwko A, Brydak L . Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Adv Exp Med Biol. 2012; 756:285-90. DOI: 10.1007/978-94-007-4549-0_35. View

13.

Paget J, Marquet R, Meijer A, van der Velden K . Influenza activity in Europe during eight seasons (1999-2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe. BMC Infect Dis. 2007; 7:141. PMC: 2216029. DOI: 10.1186/1471-2334-7-141. View

14.

Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H . The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003; 37(1):71-6. DOI: 10.1080/00365590310008749. View

15.

Kim K, Chung B, Jeon E, Kim B, Choi B, Park C . B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med. 2012; 44(8):465-72. PMC: 3429810. DOI: 10.3858/emm.2012.44.8.053. View

16.

Antonen J, Hannula P, Pyhala R, Saha H, Ala-Houhala I, Pasternack A . Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000; 86(1):56-61. DOI: 10.1159/000045713. View

17.

Cohen G, Horl W . Immune dysfunction in uremia—an update. Toxins (Basel). 2012; 4(11):962-90. PMC: 3509694. DOI: 10.3390/toxins4110962. View

18.

Temiz G, Kasifoglu N, Kiris A, Ozturk S, Sahin G, Yalcin A . Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail. 2010; 32(6):716-20. DOI: 10.3109/0886022X.2010.486498. View

19.

Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R . Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine. 2011; 30(6):1108-14. DOI: 10.1016/j.vaccine.2011.12.023. View

20.

Vogtlander N, Brown A, Valentijn R, Rimmelzwaan G, Osterhaus A . Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine. 2004; 22(17-18):2199-201. DOI: 10.1016/j.vaccine.2003.11.046. View